502 results
Page 4 of 26
CORRESP
dxyk6zikz3trq34ey5
6 Jan 21
Correspondence with SEC
12:00am
UPLOAD
1h0ofk9jj f1t8yx7s
23 Dec 20
Letter from SEC
12:00am
8-K
EX-99.1
uc8267 0jgjpa
21 Dec 20
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
8:39am
8-K/A
EX-99.1
6o4zb5tc08hpad
10 Dec 20
Financial Statements and Exhibits
4:13pm
8-K
umvtkj9
3 Dec 20
Other Events
12:00am
8-K
kedanbfirrg4t
23 Nov 20
Other Events
8:32am
8-K
ul9x357pqt8fm9zl
30 Oct 20
Amendments to Articles of Incorporation or Bylaws
4:07pm
8-K
EX-99.1
nq9 40cad7
30 Oct 20
Ligand Reports Third Quarter 2020 Financial Results
8:03am
8-K
EX-2.1
imirs9taan i5um
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
b2wpv2qrgjy
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-99.1
ghkr2gqhvnft
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-99.1
9c4iy
1 Oct 20
Contingent Value Rights Agreement
8:42am
8-K
EX-99.3
rge5 2y34zv
1 Oct 20
Contingent Value Rights Agreement
8:42am
SC TO-T/A
EX-99
ybq37jggoz7sr06
30 Sep 20
Third party tender offer statement (amended)
8:06am
SC TO-T/A
ie9 grp14qu89ckeu3a
16 Sep 20
Third party tender offer statement (amended)
6:05am
SC TO-T/A
htaqa76eswu7os
11 Sep 20
Third party tender offer statement (amended)
6:07am